NCT07300696 Functional MRI for Monitoring Progression and Assessing Trends in ILD
| NCT ID | NCT07300696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Interstitial Lung Diseases (ILD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-11-20 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this study is to investigate the utility of functional MRI to differentiate, characterize, and monitor subgroups of ILD. This can be broken down into three specific objectives: Determine if ILD features observed on high-resolution computed tomography (HRCT), such as ground glass opacities (GGO), are functionally different. Analyse MRI metrics within each subgroup to determine whether these metrics distinguish different ILDs. Assess MRI metrics longitudinally to see if these parameters change with disease progression, stability, or reversibility.
Eligibility Criteria
Inclusion Criteria: * Clinical indication for a routine HRCT because of either newly diagnosed idiopathic pulmonary fibrosis (IPF) or hypersensitivity pneumonitis (HP) or idiopathic non-specific interstitial pneumonia (iNSIP), suspected diagnosis, or follow-up * Capacity to consent * Ability to participate fully in the study (defined by the ability to lie still for the duration of imaging) Exclusion Criteria: * Pregnancy and breast feeding * Persons under the age of 18 and persons not able to give informed consent * Any medical conditions that could hinder the ability to adhere to the protocol * Any MRI contraindication, including previous allergic reactions to Gd-based MRI contrast material and renal dysfunction (eGFR \< 30 ml min/1,73 m2)
Frequently Asked Questions
Who can join the NCT07300696 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Diseases (ILD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07300696 currently recruiting?
Yes, NCT07300696 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital Heidelberg to inquire about joining.
Where is the NCT07300696 trial being conducted?
This trial is being conducted at Heidelberg, Germany, Kiel, Germany.
Who is sponsoring the NCT07300696 clinical trial?
NCT07300696 is sponsored by University Hospital Heidelberg. The trial plans to enroll 200 participants.